Evommune (NYSE:EVMN) has licensed global development rights outside Greater China to EVO570, an experimental oral drug for inflammatory diseases, in a deal with Hinova Pharmaceuticals that includes $20 million in cash and $10 million in warrants issued at signing. The company plans to test EVO570 first in rheumatoid arthritis, with a phase I study expected […]